Quali differenze in rapporto al sesso nella monoinfezione HCV PITER cohort data Loreta Kondili Istituto Superiore di Sanità.

Slides:

Advertisements

Similar presentations

The effect of improved HCV diagnosis and treatment on public health The effect of improved HCV diagnosis and treatment on public health P Mathurin Hôpital.

Advertisements

CORRELATION BETWEEN HBSAG LEVEL AND VIRAL LOAD

V. Petrenkiene*, D. Petrauskas L. Kupcinskas, Lithuanian University of Health sciences Clinic of Gastroenterology Kaunas Utility of non-invasive markers.

The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV-HIV Coinfection: HCV GT 1,2,3,4 PHOTON-2 Trial Phase 3 Molina JM, et al. IAC. 2014;

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Phase 2 Treatment.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection NIAID ERADICATE Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Sofosbuvir in HCV-HIV Coinfection & HCV GT 1,2,3 PHOTON-1 Trial Phase 3 Sulkowski MS, et al. JAMA. 2014;312:

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology. 2015;148:100-7.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.

Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-I Phase 3 Treatment Naïve Feld JJ, et.

Hepatitis web study Hepatitis web study Simeprevir in HIV Coinfection, GT-1 C212 Trial Phase 3 Treatment Naïve and Treatment Experienced Dieterich D, et.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:

National Hepatitis C Database Dr Lelia Thornton Health Protection Surveillance Centre December 2012.

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.

Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.

HCV/HIV coinfected patients in National Hospital for Tropical Diseases, Vietnam: genotypes, clinical manifestations and initial results in treating of.

Impact of weight management in chronic HCV Egyptian patients on liver fibrosis. By: Dr. Osama A. Fekry Lecturer of CN at the AUC Head of clinical Nutrition.

Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.

Prevalence of Chronic Disease & Comorbid Conditions in the CHAIN Cohort CHAIN Report Peter Messeri, Gunjeong Lee, Sara Berk Mailman School of Public.

Simple Noninvasive Systems Predict long-term Outcome of Patients With NAFLD Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

LDV/SOF 90/400 mg qd Non-randomised Open-label N = 21 W12 SVR 12 NIAID SYNERGY GT4 Kohli A. Lancet Infect Dis 2015; Juky 15, ePub ahead of print ≥ 18 years.

OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

COSMOS SOF + SMV + RBV SOF + SMV Randomisation 2 : 1 : 2 : 1* Open-label * Randomisation was stratified on genotype (1a or 1b) in both cohorts, IL28B in.

HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.

SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥

Response Guided Vs.Response Unguided Therapy K.Rajender Reddy M.D Professor of Medicine University of Pennsylvania Philadelphia, USA.

UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.

Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,

Sources of Hepatitis C Infection (U.S.) Previously Acquired (

W24 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve Early fibrosis to compensated cirrhosis No HBV or HIV co-infection N = 10 SOF + weight-based.

SOLAR-1 LDV/SOF + RBV Randomisation* of the 7 groups 1 : 1 Open-label SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease  Design W12W24 ≥ 18 years.

TURQUOISE-I OBV/PTV/r + DSV + RBV Randomisation* 1 : 1 Open-label years HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated with PEG-IFN +

HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients Roger Bedimo, MD; Henning Drechsler, MD; Song Zhang, PhD;

OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology. 2014;September.

SAPPHIRE-I Feld JJ. NEJM 2014;370: SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.

Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.

Daclatasvir + Asunaprevir in Genotype 1b HALLMARK-DUAL Study

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in HCV Genotype 4 NIAID SYNERGY (Genotype 4) Phase 2 Treatment Naïve and Treatment Experienced.

Milan J. Sonneveld,1 Bettina E. Hansen, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry.

Mun Hyuk Seong,1 Ho Kil,1 Young Seok Kim,2 Si Hyun Bae,3 Youn Jae Lee,4 Han Chu Lee,5 Byung Hak Kang,6 and Sook-Hyang Jeong1* Clinical and Epidemiological.

Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.

The Natural History of Liver Fibrosis Progression Rate in Hepatitis C Infection David Yamini, Benjamin Basseri, Anush Arakelyan, Pedram Enayati, Tram T.

Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:

Hepatitis web study Hepatitis web study Elbasvir + Grazoprevir in GT 1 and Chronic Renal Disease C-SURFER Phase 3 Treatment Naïve and Treatment Experienced.

QUALI DIFFERENZE IN RAPPORTO AL SESSO NELLA COINFEZIONE HCV/HIV? I DATI ITALIANI DALLA COORTE ICONA Antonella Cingolani Clinica Malattie Infettive, UCSC,

Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.

Glecaprevir-Pibrentasvir in GT 1-6 with Renal Disease EXPEDITION-4

National Hepatitis C Database

Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced

ARV-trial.com RUBY-I Study, cohort 2: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for HCV genotype 1 with renal impairment Design Open label W12.

Phase 3 Treatment-Naïve and Treatment-Experienced

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

Clinical outcome after SVR: Veterans Affairs

Starting Strong: Initial Evaluation of the Patient With HCV

Simeprevir in HIV Coinfection, GT-1 C212 Trial

EXPEDITION-V Study: GLE/PIB in patients with renal impairment

Clinical outcome after SVR: ANRS CO22 HEPATHER

Impact of metabolic risk factors on HCC

Phase 3 Treatment-Naïve and Treatment-Experienced

Incidence of HCC after HCV treatment with DAAs: ERCHIVES

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

Presentation transcript:

Quali differenze in rapporto al sesso nella monoinfezione HCV PITER cohort data Loreta Kondili Istituto Superiore di Sanità

Enrollmet in the PITER cohort as by October patients enrolled from 80 clinical centers PITER is a well rapresentative sample of patients in care in Italy.

Web- Based Data Collection

Distribution of patients enrolled in by gender Women 3317 (44%) Mean age years Men 4175 (56%) Mean age years

Distribution of patients enrolled in by gender and age groups

Body Max Index according to gender Men

Fibrosis Distribution according to gender and age groups

HCV Genotypes Distribution according to gender Overall Genotype Distribution Gt1 = 65%; Gt2=15%;Gt3=11%;Gt4=6% Other 1%

Distribution of HCV Genotypes in patients with Clinical cirrhosis

Coinfections Women 130/3317= 4% 1869 N.D. HIV status 130/1656 =8% HBsAg 26/2408 =1% (823 ND HBsAg positivity) Men 319/4175 =7.6% 1869 N.D. HIV status 319/2306 =14% Positivity 26/3079 =2% (960 ND HBsAg positivity) HIV Positivity

Previous Therapeutic history according to gender Naive: 3655pt: Men: 1914 Women: 1741 Experienced:3653pt Men 2159 Women 1494

Distribution of Fibrosis in treatment experienced patients Men

Distribution of Fibrosis in Naive patients F0-1 51% F2 14% F0-F1:51% F2:14% F3:10% F4:23% Women F0-F1:42% F2:13% F3:11% F4:34% Men

Factors correlating with cirrhosis Factors N 6831 OR Univariate CI 95% OR Adjusted CI 95% Mean Age Gender F vs M3034/ Previous Alcohol use yes/No use1435/ Actual Alcohol use/no use1083/ BMI >= 25 vs BMI<252606/ BM I>= 30 vs BMI<25726/ HCV Genotype 1 vs 23996/ vs 2655/ vs 2446/ Others vs 298/ Diabetes vs Non Diabetes913/ >2 times Increased Gamma GT vs NR965/ >2 times Increased ALT vs NR1748/ >2 times Increased AST vs NR1647/ PLT: vs > / PLT: vs> /

Comorbidity according to Gender Gender Comorbidity Male N (4174) %Female N (3317) % Autoimune * Cardiovascular * Diabetes Haematologic Neurologic Osteoarticolar * Psychiatric Renal Tumours * Other

Conclusions Compared to men patients enrolled Women account for 46 % of overall patients and have a mean age one decade older. Genotype 1 and 2 are more frequently present overall and in women with cirrhosis F0-F1 is significantly more prevalent in both age groups below and over 60 years of age Women naive and experienced to previous antiviral therapies have more frequently fibrosis F0-F1 than F4 cirrhosis Women gender is inversly correlated to liver cirrhosis ; Women with cirrhosis are older Women have more frequent cardiovascular disease, osteoarticolar disease and tuomors.